Recent Updates
Recently added Catalysts

vehicle

Phase 1

Pain | Small molecule | Pain |Pfizer, Inc.|Last Updated: Feb 28, 2013

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLED
Total Trials2
Total Enrollment284
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01771822Ibuprofen 5% Topical Gel CIPTPHASE1 COMPLETED 50Jan 1, 2013Feb 1, 2013Feb 28, 20131 United States
NCT01787448RIPT of Ibuprofen Topical GelPHASE1 COMPLETED 234Jan 1, 2013Feb 1, 2013Feb 28, 20131 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Assessment of local skin irritation at patch sites
Daily for 21 days, Days 2 through 22
Dermal sensitization potential
24-72 hours after last patch removal
Secondary Endpoints
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Days 1 through 22, + 28 days after last product administration
Cumulative Irritancy
48-72 hours after each patch application
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
Ibuprofen 5% topical gelEXPERIMENTAL -
Topical gel vehicleEXPERIMENTAL -
Sodium lauryl sulfate 0.2%ACTIVE_COMPARATOR -
Sodium chloride solution 0.9% (saline)SHAM_COMPARATOR -
Sodium lauryl sulfate 0.1%ACTIVE_COMPARATOR -
Interventions
NameTypeDescription
Ibuprofen 5% topical gelDRUG0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
Topical gel vehicleDRUG0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
Sodium lauryl sulfate 0.2%DRUG0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
Sodium chloride solution 0.9% (saline)DRUG0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
Sodium lauryl sulfate 0.1%DRUG0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: Healthy male and/or female subjects (to be confirmed by medical history) 18 years of age or older, female subjects of childbearing potential and males who are using an acceptable form of birth control, subjects who are free of any systemic or dermatologic disorder Exclusion Cri...

Countries:United States
Unlock Eligibility Criteria